Olatorepatide for Hidradenitis Suppurativa
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and helps support weight loss.
The study is looking at:
* What side effects olatorepatide might cause
* How well olatorepatide works
* How much olatorepatide is in the blood at different times
* If the body makes antibodies to olatorepatide, which may cause olatorepatide to not work as well
Who Is on the Research Team?
Clinical Trial Management
Principal Investigator
Regeneron Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for adults who have had moderate to severe hidradenitis suppurativa (HS) for at least 6 months, with HS lesions in at least 2 body areas and a BMI of 27 or higher. Participants must agree to use daily antiseptics on affected skin.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Olatorepatide
Trial Overview
The study compares the experimental drug olatorepatide to a placebo in people with HS and overweight or obesity. It aims to see if olatorepatide improves HS symptoms, quality of life, and supports weight loss.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Regeneron Pharmaceuticals
Lead Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.